2021
Prescribers’ satisfaction with delivering medications for opioid use disorder
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Kim H, Madden LM, Haram E, Molfenter T. Prescribers’ satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, And Policy 2021, 16: 78. PMID: 34663379, PMCID: PMC8521499, DOI: 10.1186/s13011-021-00413-7.Peer-Reviewed Original ResearchConceptsType of MOUDOpioid use disorderPrescriber satisfactionPrescriber characteristicsUse disordersXR-naltrexoneBuprenorphine treatmentExtended-release naltrexoneUS opioid epidemicOverall satisfactionRelease naltrexoneGreater overall satisfactionClinical trialsOpioid epidemicMethodsAs partMOUDWeb-based surveyPatient censusPrescribersMedicationsBuprenorphineDisordersTreatmentCurrent studyHigh levelsChapter 9 Outpatient opioid use disorder treatment for the ID physician
Muthulingam D, Madden L, Altice F. Chapter 9 Outpatient opioid use disorder treatment for the ID physician. 2021, 161-187. DOI: 10.1016/b978-0-323-68328-9.00009-6.Peer-Reviewed Original ResearchOpioid use disorderOUD treatmentOpioid use disorder treatmentExtended-release naltrexoneInfectious disease cliniciansInitiation of treatmentSpecial clinical considerationsUse disorder treatmentHIV practiceID cliniciansOUD pharmacotherapyIntegrated care deliveryID physiciansMedication optionsOpioid epidemicTreatment expansionTreatment accessUse disordersAddiction specialistsClinical considerationsOUD managementDisorder treatmentGeneral IDCare deliveryPractice settings
2017
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial
Molfenter T, Knudsen HK, Brown R, Jacobson N, Horst J, Van Etten M, Kim JS, Haram E, Collier E, Starr S, Toy A, Madden L. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science 2017, 12: 135. PMID: 29141653, PMCID: PMC5688699, DOI: 10.1186/s13012-017-0665-x.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction treatment fieldPrevalence of OUDSubstantial public health significanceOpioid misuse epidemicExtended-release naltrexonePrimary treatment outcomeEvidence-based pharmacotherapyAddiction treatment workforceSignificant health issuePublic health significanceAddiction treatment providersNaltrexone patientsNon-medical useOUD pharmacotherapyTreatment fieldOUD patientsBuprenorphine patientsPrescription opioidsCluster RCTIntervention periodTreatment outcomesImplementation interventionsOverdose deathsUse disordersPatient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatment